Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Ver gráficos interativos e demonstrações completas →
| Demonstração de resultados | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Receita total | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| Lucro bruto | — | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | $0M | — | — | — |
| Margem Bruta % | — | — | — | — | — | — | — | — | — | — | — |
| Resultado Operacional (EBIT) | ($559M) | ($533M) | ($438M) | ($270M) | ($208M) | ($156M) | ($108M) | ($60M) | $0M | $0M | ($137M) |
| % de margem operacional | -7877.5% | — | — | — | — | — | — | — | — | — | — |
| Resultado líquido | ($538M) | ($506M) | ($414M) | ($259M) | ($211M) | ($157M) | ($107M) | ($66M) | $0M | $0M | ($137M) |
| Margem Líquida % | -7585.9% | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($539M) | ($505M) | ($413M) | ($259M) | ($198M) | ($157M) | ($108M) | ($66M) | $0M | — | — |
| Lucro por ação (EPS) | $-2.81 | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-0.00 | — | $-13.67 |
| Ações em circulação (M) | 206M | 182M | 152M | 138M | 123M | 110M | 88M | 43M | 14M | — | 10M |
Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.
Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de IMVT. /companies/us/IMVT
As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.
About TickerBase · Data methodology & sources · Privacy · Terms